Prostate adenocarcinoma · Lutetium-177 PSMA-617 radioligand therapy

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-LUTETIUM-PSMA`

ID	`IND-PROSTATE-MCRPC-2L-LU-PSMA`
Type	Indication
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	`DIS-PROSTATE`
Sources	`SRC-NCCN-PROSTATE-2025` `SRC-VISION-PSMA-SARTOR-2021`

Notes

REG-LUTETIUM-PSMA is the required regimen — 7.4 GBq IV q6w × 6 cycles per VISION. Dose calculated per cycle, not weight-based (unlike Ra-223). Dosimetry with each administration in specialized theranostics centers. Salivary gland and kidney uptake are dose-limiting organs — xerostomia is the most common non-hematologic Grade ≥3 adverse event (~7%). Bone marrow suppression: Grade 3/4 anemia ~12%, thrombocytopenia ~8%.

Used By

Algorithms

ALGO-PROSTATE-MCRPC-1L - ALGO-PROSTATE-MCRPC-1L
ALGO-PROSTATE-MCRPC-2L - ALGO-PROSTATE-MCRPC-2L

Contraindications

CI-PROSTATE-LUTETIUM-VISCERAL-ONLY - CI-PROSTATE-LUTETIUM-VISCERAL-ONLY

Handbook Chapters

HB-PROSTATE-MCRPC-1L - Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning

Indication

IND-PROSTATE-MCRPC-2L-CABAZITAXEL - IND-PROSTATE-MCRPC-2L-CABAZITAXEL
IND-PROSTATE-MCRPC-2L-RADIUM223 - IND-PROSTATE-MCRPC-2L-RADIUM223